secwatch.observer — SEC 8-K summary
======================================

Issuer:     ADIAL PHARMACEUTICALS, INC. (ADIL)
CIK:        0001513525
Form:       8-K
Filed at:   2025-03-21T23:59:59+00:00
Accession:  0001013762-25-000999
Event type: leadership
Sentiment:  neutral
Materiality: 0.25
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Adial Pharmaceuticals appoints Tony Goodman as COO with $300K base salary, three-year term
--------------------------------------------------------------------------------

- Tony Goodman appointed Chief Operating Officer effective April 1, 2025, under three-year employment agreement.
- Base salary of $300,000 per year; eligible for discretionary bonus up to 30% of base.
- Severance: six months for without-cause termination; 12 months if termination follows a change of control.
- Goodman had been serving as COO since January 2024 via consulting agreement with The Keswick Group; that agreement terminates.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1513525/000101376225000999/0001013762-25-000999-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1513525/000101376225000999/ea0235166-8k_adial.htm
  HTML page:      https://secwatch.observer/filing/0001013762-25-000999

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer